Observed bromodomain flexibility reveals histone peptide- and small molecule ligand-compatible forms of ATAD2.Poncet-Montange, G., Zhan, Y., Bardenhagen, J.P., Petrocchi, A., Leo, E., Shi, X., Lee, G.R., Leonard, P.G., Geck Do, M.K., Cardozo, M.G., Andersen, J.N., Palmer, W.S., Jones, P., Ladbury, J.E.
(2015) Biochem.J. 466: 337-346
- PubMed: 25486442
- DOI: 10.1042/BJ20140933
- Primary Citation of Related Structures:
- PubMed Abstract:
Preventing histone recognition by bromodomains emerges as an attractive therapeutic approach in cancer. Overexpression of ATAD2 (ATPase family AAA domain-containing 2 isoform A) in cancer cells is associated with poor prognosis making the bromodomain ...
Preventing histone recognition by bromodomains emerges as an attractive therapeutic approach in cancer. Overexpression of ATAD2 (ATPase family AAA domain-containing 2 isoform A) in cancer cells is associated with poor prognosis making the bromodomain of ATAD2 a promising epigenetic therapeutic target. In the development of an in vitro assay and identification of small molecule ligands, we conducted structure-guided studies which revealed a conformationally flexible ATAD2 bromodomain. Structural studies on apo-, peptide-and small molecule-ATAD2 complexes (by co-crystallization) revealed that the bromodomain adopts a 'closed', histone-compatible conformation and a more 'open' ligand-compatible conformation of the binding site respectively. An unexpected conformational change of the conserved asparagine residue plays an important role in driving the peptide-binding conformation remodelling. We also identified dimethylisoxazole-containing ligands as ATAD2 binders which aided in the validation of the in vitro screen and in the analysis of these conformational studies.
*Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Unit 1954, 1515 Holcombe Blvd, Houston, TX 77030, U.S.A.